Abstract
The aim of the study was to evaluate in man the dose-effect relationship of ibopamine solution 0.25%, 0.50%, and 1% on the pupillary diameter and the pupillary reflex to light stimulus and near vision. A cross-over study was performed in comparison with a placebo and with tropicamide solution 1% in 18 healthy volunteers. The results show that ibopamine 1% determines a marked mydriatic effect. At the doses used, it produces maximum increase of the pupillary diameter with a dose-effect relationship which does not depart significantly from a straight line. The maximum mydriatic effect of ibopamine 1% is significantly greater than that of tropicamide 1%. The mydriatic effect of ibopamine lasts for about 3 h; that of tropicamide lasts longer. Tropicamide 1% markedly and for a long period inhibits the pupillary reflex both to light and to near vision. The effect of ibopamine 1% on the pupillary reflext to near vision is slight, while on the reflex to light stimulus it is essentially comparable to that of tropicamide.
| Original language | English |
|---|---|
| Pages (from-to) | 150-156 |
| Number of pages | 7 |
| Journal | Arzneimittel-Forschung/Drug Research |
| Volume | 40 |
| Issue number | 2 |
| Publication status | Published - 1990 |
Fingerprint
Keywords
- Dopaminergic drugs
- Ibopamine, clinical studies
- Mydriatics
- Ophthalmics
- Tropicamide, clinical studies
ASJC Scopus subject areas
- Chemistry(all)
- Organic Chemistry
- Drug Discovery
- Pharmacology
Cite this
Dynamic evaluation by TV-pupillometry of the mydriatic effect of ibopamine solution. Controlled studies. / Micieli, G.; Tassorelli, C.; Iannacchero, R.; Lodola, E.; Barbieri, P.; Nappi, G.
In: Arzneimittel-Forschung/Drug Research, Vol. 40, No. 2, 1990, p. 150-156.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Dynamic evaluation by TV-pupillometry of the mydriatic effect of ibopamine solution. Controlled studies
AU - Micieli, G.
AU - Tassorelli, C.
AU - Iannacchero, R.
AU - Lodola, E.
AU - Barbieri, P.
AU - Nappi, G.
PY - 1990
Y1 - 1990
N2 - The aim of the study was to evaluate in man the dose-effect relationship of ibopamine solution 0.25%, 0.50%, and 1% on the pupillary diameter and the pupillary reflex to light stimulus and near vision. A cross-over study was performed in comparison with a placebo and with tropicamide solution 1% in 18 healthy volunteers. The results show that ibopamine 1% determines a marked mydriatic effect. At the doses used, it produces maximum increase of the pupillary diameter with a dose-effect relationship which does not depart significantly from a straight line. The maximum mydriatic effect of ibopamine 1% is significantly greater than that of tropicamide 1%. The mydriatic effect of ibopamine lasts for about 3 h; that of tropicamide lasts longer. Tropicamide 1% markedly and for a long period inhibits the pupillary reflex both to light and to near vision. The effect of ibopamine 1% on the pupillary reflext to near vision is slight, while on the reflex to light stimulus it is essentially comparable to that of tropicamide.
AB - The aim of the study was to evaluate in man the dose-effect relationship of ibopamine solution 0.25%, 0.50%, and 1% on the pupillary diameter and the pupillary reflex to light stimulus and near vision. A cross-over study was performed in comparison with a placebo and with tropicamide solution 1% in 18 healthy volunteers. The results show that ibopamine 1% determines a marked mydriatic effect. At the doses used, it produces maximum increase of the pupillary diameter with a dose-effect relationship which does not depart significantly from a straight line. The maximum mydriatic effect of ibopamine 1% is significantly greater than that of tropicamide 1%. The mydriatic effect of ibopamine lasts for about 3 h; that of tropicamide lasts longer. Tropicamide 1% markedly and for a long period inhibits the pupillary reflex both to light and to near vision. The effect of ibopamine 1% on the pupillary reflext to near vision is slight, while on the reflex to light stimulus it is essentially comparable to that of tropicamide.
KW - Dopaminergic drugs
KW - Ibopamine, clinical studies
KW - Mydriatics
KW - Ophthalmics
KW - Tropicamide, clinical studies
UR - http://www.scopus.com/inward/record.url?scp=0025159386&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025159386&partnerID=8YFLogxK
M3 - Article
C2 - 2334454
AN - SCOPUS:0025159386
VL - 40
SP - 150
EP - 156
JO - Arzneimittel-Forschung/Drug Research
JF - Arzneimittel-Forschung/Drug Research
SN - 0004-4172
IS - 2
ER -